The role of systemic inflammatory response index (SIRI) and tumor-infiltrating lymphocytes (TILs) in the prognosis of patients with laryngeal squamous cell carcinoma

Author:

Wang Tian1,Zhang Duo1,Tang Di1,Heng Yu1,Lu Li-ming2,Tao Lei1

Affiliation:

1. Fudan University School of Medicine

2. Shanghai Jiaotong University School of Medicine

Abstract

Abstract Objectives: Systemic inflammatory response index (SIRI) values and tumor-infiltrating lymphocytes (TILs) are associated with the prognosis of various tumors. There is minimal evidence of those two as prognostic markers in laryngeal squamous cell carcinoma (LSCC). In this study, we aimed to examine the predictive value of SIRI and tumor-infiltrating CD3+/CD4+/CD8+T-cells in the prognosis of patients who underwent partial or total laryngectomy. Study Design: A total of 78 patients with LSCC who underwent total or partial laryngectomy at the Eye, Ear, Nose, and Throat Hospital of Fudan University between 2013 and 2015 were retrospectively analyzed. Methods: The tumor tissues of 78 LSCC patients were retrospectively evaluated using immunohistochemical staining for CD3+/CD4+/CD8+ -cells. The overall survival (OS) and disease-free survival (DFS) rates were recorded using the Kaplan-Meier method. Results: Patients with high immunoscore (IS) (3~4) had prolonged survival (P<0.001 for OS). High SIRI values were independently associated with poorer OS and DFS (P=0.018 for OS; P=0.016 for DFS). CD8+TILs and SIRI values showed a positive association (Pearson’s r = -0.2988, P<0.05). Patients with low SIRI values and high IS had better 5-year OS and DFS than those with high SIRI values and low IS (P<0.001 for OS; P=0.0014 for DFS). Patients with ‘hot’ tumor had a higher 5-year OS than those with ‘excluded’ or ‘cold’ phenotype. Conclusions: The SIRI values and the density of TILs may help predict LSCC patients' outcomes after surgery. The combination of SIRI and IS may be a new component of the tumor, nodes, and metastases (TNM) classification of cancer and prognostic factor for T cell-target immunotherapy.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3